Enhancing the Presentation and Evaluation of Cumulative Post-Marketing Safety Data: A Pilot Study

被引：0
|
作者：
Gilchrist, A.
Layton, D.
Fogg, C.
Shakir, S.
机构：
[1] Drug Safety Res Unit, Southampton, Hants, England
[2] Univ Portsmouth, Portsmouth, Hants, England
来源：
DRUG SAFETY | 2011年 / 34卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
下载
收藏
页码：968 / 968
页数：1
相关论文
共 50 条
  • [21] Re-evaluation for the safety of levamisole in post-marketing: Literature survey
    Zheng, Rong-yuan
    Yang, Xue-zhi
    Zhu, Zhen-guo
    Ying, Wei-yong
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 : S206 - S207
  • [22] Post-marketing drug safety sources: An evaluation of the FDA's drug safety communications
    Aldayel, Atheer
    Alghamdi, Maha
    Almutairi, Abdulaali
    Al-Harbi, Fawaz F.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 302 - 302
  • [23] Ibrutinib: A post-marketing safety analysis.
    Elias, Rawad
    Pudusseri, Anita
    Akinboro, Oladimeji
    White, Paul S.
    Sarosiek, Shayna
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] Post-marketing Safety Experience with Vedolizumab: Malignancy
    Bhayat, Fatima
    Blake, Aimee
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S313 - S314
  • [25] Post-marketing safety profile of pethidine in Indonesia
    Haposan, Jonathan Hasian
    Thobari, Jarir At
    Nurwahidin, Muhammad
    Chandra, Lukman Ade
    Hidayati, Nastia
    Dewi, Rianiasa Karunia
    Pudjiati, Dyah Juliana
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 226 - 227
  • [26] Post-marketing surveillance of the safety of levofloxacin in Japan
    Yamaguchi, Hiroki
    Kawai, Hitomi
    Matsumoto, Takuyuki
    Yokoyama, Hiroo
    Nakayasu, Toshio
    Komiya, Masahiro
    Shimada, Jingoro
    CHEMOTHERAPY, 2007, 53 (02) : 85 - 103
  • [27] POST-MARKETING SAFETY STUDIES Three design aspects for high quality post-marketing cohort studies
    Fralick, Michael
    Kesselheim, Aaron S.
    BMJ-BRITISH MEDICAL JOURNAL, 2017, 357
  • [28] Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals
    Andreas Schick
    Kathleen L. Miller
    Michael Lanthier
    Gerald Dal Pan
    Clark Nardinelli
    Drug Safety, 2017, 40 : 497 - 503
  • [29] Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals
    Schick, Andreas
    Miller, Kathleen L.
    Lanthier, Michael
    Dal Pan, Gerald
    Nardinelli, Clark
    DRUG SAFETY, 2017, 40 (06) : 497 - 503
  • [30] Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients
    Di Rienzo, V
    Pagani, A
    Parmiani, S
    Passalacqua, G
    Canonica, GW
    ALLERGY, 1999, 54 (10) : 1110 - 1113
12345